Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail (Details)

v3.2.0.727
Condensed Consolidated Financial Statements Detail (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2012
Feb. 28, 2010
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]              
Antidilutive securities excluded from computation of earnings per share (in shares)     27,449,000 9,849,000 26,937,000 8,486,000  
Numerator [Abstract]              
Net loss, Basic     $ (23,759) $ (11,897) $ (45,477) $ (16,584)  
Adjustment for revaluation of contingent warrant liabilities     0 (7,616) 0 (27,150)  
Net loss, Diluted     $ (23,759) $ (19,513) $ (45,477) $ (43,734)  
Denominator Abstract]              
Weighted average shares outstanding used for basic net loss per share (in shares)     117,540,000 106,927,000 116,870,000 106,545,000  
Effect of dilutive warrants (in shares)     0 7,199,000 0 8,503,000  
Weighted average shares outstanding and dilutive securities used for diluted net loss per share (in shares)     117,540,000 114,126,000 116,870,000 115,048,000  
Accrued and other liabilities [Abstract]              
Accrued payroll and other benefits     $ 2,851   $ 2,851   $ 3,061
Accrued management incentive compensation     2,300   2,300   4,295
Accrued clinical trial costs     1,081   1,081   1,424
Other     1,209   1,209   1,112
Total     $ 7,441   7,441   $ 9,892 [1]
Class of Warrant or Right [Line Items]              
Reclassification of contingent warrant liability to equity upon exercise of warrants         $ 3,088 $ 2,526  
Cashless exercise of warrants (in shares)     1,602,575   1,602,575    
Two Year Warrants Issued in December 2014 [Member]              
Class of Warrant or Right [Line Items]              
Warrants outstanding (in shares)     8,097,165   8,097,165   8,097,165
Exercise price of warrants (in dollars per share)             $ 7.90
Fair value of warrant liability     $ 4,000   $ 4,000   $ 5,200
Gain (loss) on revaluation of warrant liability         $ 1,200    
Warrant term             2 years
Five Year Warrants Issued in March 2012 [Member]              
Class of Warrant or Right [Line Items]              
Warrants outstanding (in shares) 14,834,577   10,506,093   10,506,093   12,109,418
Exercise price of warrants (in dollars per share) $ 1.76            
Fair value of warrant liability     $ 25,000   $ 25,000   $ 26,700
Gain (loss) on revaluation of warrant liability         (1,400)    
Gain (loss) on revaluation of warrant liability related to exercised warrants         $ 500    
Warrant term 5 years            
Warrants exercise (in shares)     1,603,325   1,603,325    
Five Year Warrants Issued in February 2010 [Member]              
Class of Warrant or Right [Line Items]              
Warrants outstanding (in shares)   1,260,000          
Exercise price of warrants (in dollars per share)   $ 10.50          
Warrant term   5 years          
Warrants Issued to Private Investors [Member]              
Class of Warrant or Right [Line Items]              
Warrants issued (in shares)     855,128   855,128    
Demand Deposits [Member]              
Cash and Cash Equivalents [Line Items]              
Cash equivalents     $ 18,900   $ 18,900   10,800
Money Market Funds [Member]              
Cash and Cash Equivalents [Line Items]              
Cash equivalents     $ 32,100   $ 32,100   $ 67,600
Common Stock Options and Restricted Stock [Member]              
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]              
Antidilutive securities excluded from computation of earnings per share (in shares)     8,362,000 7,939,000 7,850,000 6,576,000  
Warrants for Common Stock [Member]              
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]              
Antidilutive securities excluded from computation of earnings per share (in shares)     19,087,000 1,910,000 19,087,000 1,910,000  
[1] The condensed consolidated balance sheet as of December 31, 2014 has been derived from the audited consolidated financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014.